Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Looking for the Next Dendreon? Consider Oncothyreon
- VFC submits: Dendreon DNDN shocked the investing world last month after reporting positive Phase III results for it's prostate cancer immunotherapy treatment Provenge. Although the company still must overcome the hurdle of FDA approval, investors are out searching for the next Dendreon, and VFC's Stock House, as always, is...
- External links 2009-05-17
- Titan Pharmaceuticals: Back in Business
- VFC submits: Just weeks ago, Titan Pharmaceuticals (TTNP.PK) was a company on the brink. The stock was trading for five cents, or below, and most corporate offices had been cleared out and were standing empty. After the failures of Spheramine and the FDA non-approval of Ilperidone, Probuphine was the...
- External links 2009-05-21
- Gilead Sciences: Stock in Decline or Great Buying Opportunity?
- VFC submits: After trading at forty eight dollars just three weeks ago on news of the Swine Flu pandemic , shares of Gilead Sciences GILD have embarked on a downward trend that now has the stock trading below forty three dollars, closing Thursday at $42.56. Gilead Sciences is a...
- External links 2009-05-22
- Epicept May Have Potential, But How Long are Investors Willing to Wait?
- VFC submits: When the European Commission decided to approve Ceplene last October, Epicept EPCT looked to be as safe an investment as any since the only thing that stood in the way of Epicept and a revenue stream was the search for a marketing partner. Now, seven months later,...
- External links 2009-05-22
- Epicept Still Searching for Partner to Help Launch Its Latest Drug
- VFC submits: Epicept Corporation EPCT announced on Tuesday that a partner has been found for Ceplene, the company's drug that is approved in the European Union for maintenance therapy for adult patients with AML in first remission. However, the partnership agreement is not in preparation for the commercial launch...
- External links 2009-06-03
- Stock Watch: Biodelivery Sciences Has Nearly Tripled Over Past Months
- VFC submits: BDSI Sets 52-Week HighStock Watch: BDSIStocks on the Move: BDSIVFC's 2009 Stock Picks, Part IIIBiodelivery Sciences BDSI set a new 52-week high of six dollars during trading on Tuesday and closed not too far off that mark at $5.93. by VFC's Stock House
- External links 2009-06-03
- Antigenics: Rallying Cancer Vaccine Stock
- VFC submits: AGEN's Contrary IndicatorAGEN Stock WatchEarly last week Antigenics' AGEN stock dropped 13% on fairly heavy volume before rebounding in the days leading up to the American Society of Clinical Oncology (ASCO) annual meeting that took place in Orlando, Florida this past weekend. by VFC's Stock House
- External links 2009-06-03
- EpiCept Trading on High Volume
- VFC submits: Three days ago I wrote that Epicept EPCT was a stock worth watching as the company signed a partner to distribute Ceplene in a world wide named patient program.The news that Ceplene, Epicept's drug that is intended to prevent leukemia relapse in patients with Acute Myeloid Leukemia...
- External links 2009-06-05
- Insmed Stock Rising on High Volume, But Still a Good Buy
- VFC submits: Based on the volatility of the stock that has been accompanied by days of high trading volume, I've been predicting for weeks now that Insmed INSM was gearing up to release some significant news, most likely regarding the preliminary data collected from a Phase II trial measuring...
- External links 2009-06-08
- CEL-SCI: A Great Buy Looking for Attention
- VFC submits: Cel Sci Corp CVM on Tuesday released yet another announcement regarding their L.E.A.P.S. technology and its possible ability to treat or prevent the Swine Flu.According to the PR, the company by VFC's Stock House
- External links 2009-06-10
- Insmed's Good End of the Deal
- VFC submits: When Insmed Inc. INSM sold its Follow-On-Biologics [FOB] pipeline to Merck & Co. MRK for $130 million back in March, it may have been a better deal for the company than thought at the time.With four FOB candidates moving steadily along in the pipeline, Insmed prepared to...
- External links 2009-07-20
- Insmed's Monday Morning Press Release: Reading Between the Lines
- VFC submits: Insmed INSM issued an early morning press release on Monday stating that the company, for the most part, will cease all operations regarding the advancement of IPLEX. The PR was accompanied by a trading halt that was in effect for about half an hour.According to the report,...
- External links 2009-07-28
- Not Buying Cel Sci's Swine Flu PR
- VFC submits: Shares of Cel Sci Corp. CVM enjoyed a small spike to over fifty cents after the company released yet another press release relating its LEAPS technology for the treatment of the H1N1 Swine Flu. According to the PR, the company has expanded the scope towards creating...
- External links 2009-08-18
- BioDelivery Sciences: Attractive Under $5
- VFC submits: Shares of BioDelivery Sciences BDSI traded up about five percent during mid day trading on Wednesday after the company issued a press release announcing that it has "retained ICR, a leading investor relations and strategic advisory firm, to assist in the Company's shareholder communications program." ...
- External links 2009-08-20
- Cell Therapeutics Looks Good, Antigenics Looks Better
- VFC submits: In response to a number of requests that I've received via email or comments asking for 'VFC's Take' on numerous stocks that readers have found, I'll do my best to address as many as I can, as long as everyone takes a few things into account while...
- External links 2009-09-08
- ImmunoCellular Therapeutics: Wait for the Hype to Die Down
- VFC submits: An anonymous reader comments on ImmunoCellular Therapeutics (IMUC.OB): Hey VFC, I was wondering what your thoughts are on IMUC. It was recently featured on BioMedReports.com. It has a small market cap and still in the early stages of development. I was wondering if you think this...
- External links 2009-09-15
- FDA Approval Confirms Eurand's Long-Term Growth Potential
- VFC submits: A comment from Kenneth regarding Eurand EURX: Thanks so much for taking the time to reply our many queries. I was wondering if you see any upside potential in Eurand EURX. The company recently received FDA approval for Zenpep, the only FDA-approved pancreatic...
- External links 2009-09-15
- Chelsea Therapeutics: Not Worth Speculating
- VFC submits: A comment from an anonymous poster regarding Chelsea Therapeutics CHTP: Hi VFC! What are your thoughts on CHTP Chelsea Therapeutics? Does it pass your initial "smell test"? by VFC's Stock House
- External links 2009-09-15
- Discovery Labs: Too Much Recent Turmoil
- VFC submits: From an anonymous poster regarding Discovery Labs DSCO: Hi VFC, What about DSCO? Made a big move today - been around a long time. by VFC's Stock House
- External links 2009-09-15
- Antigenics: Why So Many Shorts?
- VFC submits: From a reader's comment on Antigenics AGEN: VFC, Why do you think there are 16.5 Million shares short on AGEN? Worries me. by VFC's Stock House
- External links 2009-09-15
- << Previous
- page 1 of 3
- Next >>
